Endonovo Therapeutics Inc Quick Ratio (ENDV) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Endonovo Therapeutics Inc   (ENDV)

Endonovo Therapeutics Inc 's Quick Ratio

ENDV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




Within Medical Equipment & Supplies industry Endonovo Therapeutics Inc booked the highest Quick Ratio than Endonovo Therapeutics Inc in the third quarter 2023. While total ranking remained the same in the Q3 2023 compared to the second quarter 2023 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents ENDV´s has?
What are ENDV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENDV Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 32.96 % 30.33 % 28.91 % 88.58 % -12.1 %
Y / Y Cash & cash equivalent Change - - -81.76 % -99.89 % 303.68 %
Quick Ratio MRQ - 0 0 0 0
ENDV's Total Ranking # # # # #
Seq. Current Liabilities Change 2.42 % -9.22 % -23.65 % 87.3 % 0.39 %
Seq. Cash & cash equivalent Change - 197.95 % 11065.31 % -99.58 % -



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Endonovo Therapeutics Inc 's Current Liabilities $ 24 Millions Visit ENDV's Balance sheet
Endonovo Therapeutics Inc 's Cash & cash equivalent $ 0 Millions Visit ENDV's Balance sheet
Source of ENDV's Sales Visit ENDV's Sales by Geography


Cumulative Endonovo Therapeutics Inc 's Quick Ratio

ENDV's Quick Ratio for the trailling 12 Months

ENDV Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 44.7 % 32.22 % 22.77 % 17.53 % -2.1 %
Y / Y Cash & cash equivalent TTM Growth -74.19 % -55.96 % -78.66 % -55.3 % 48.76 %
Quick Ratio TTM 0 0 0 0 0
Total Ranking TTM # 4107 # 4160 # 3910 # 4102 # 4104
Seq. Current Liabilities TTM Growth 5.88 % 5.7 % 6.44 % 21.47 % -3.25 %
Seq. Cash & cash equivalent TTM Growth -34.65 % 95.39 % -58.93 % -50.77 % 11.48 %

Quick ratio ranking by company, industry and sector >> Back to ENDV Financial Strength Comparisons >> Go to Compare ENDV Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2023 to $23.70 millions, cumulative Quick Ratio